Scarica l'app Stockscreener
20.85
4.77%
0.95
Dopo l'orario di chiusura:
20.85
Precedente Chiudi:
$19.90
Aprire:
$20.01
Volume 24 ore:
242.24K
Relative Volume:
0.77
Capitalizzazione di mercato:
$670.54M
Reddito:
$4.12M
Utile/perdita netta:
$-56.68M
Rapporto P/E:
-3.7616
EPS:
-5.5429
Flusso di cassa netto:
$-51.44M
1 W Prestazione:
+2.26%
1M Prestazione:
+3.94%
6M Prestazione:
-13.59%
1 anno Prestazione:
-21.23%
Intervallo 1D:
$19.75
$21.18
Intervallo di 1 settimana:
$18.08
$21.18
Portata 52W:
$13.37
$32.27
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Nome
Dianthus Therapeutics Inc
Settore
Industria
Telefono
929-999-4055
Indirizzo
7 TIMES SQUARE, NEW YORK
Confronta DNTH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
20.85 | 607.88M | 4.12M | -56.68M | -51.44M | -5.5429 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-02 | Iniziato | William Blair | Outperform |
| 2024-12-20 | Iniziato | TD Cowen | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-26 | Iniziato | Robert W. Baird | Outperform |
| 2024-06-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-02-15 | Iniziato | Stifel | Buy |
| 2023-12-26 | Iniziato | Jefferies | Buy |
| 2023-11-22 | Iniziato | Wedbush | Outperform |
| 2023-10-30 | Iniziato | Guggenheim | Buy |
| 2023-09-28 | Iniziato | Raymond James | Outperform |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-08-20 | Ripresa | Goldman | Neutral |
| 2021-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Reiterato | B. Riley Securities | Buy |
| 2021-06-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-18 | Iniziato | B. Riley Securities | Buy |
| 2021-01-07 | Iniziato | Mizuho | Buy |
| 2020-06-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-03-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
Mostra tutto
Dianthus Therapeutics Inc Borsa (DNTH) Ultime notizie
Is this a good reentry point in Dianthus Therapeutics Inc.Sell Signal & Stock Market Timing Techniques - Newser
Dianthus Therapeutics Inc.’s volatility index tracking explainedAnalyst Upgrade & Growth Oriented Trading Recommendations - Newser
Dianthus Therapeutics Inc. stock trend forecast2025 Year in Review & Real-Time Stock Entry Alerts - Newser
What earnings revisions data tells us about Dianthus Therapeutics Inc.2025 Key Lessons & Breakout Confirmation Alerts - Newser
How to forecast Dianthus Therapeutics Inc. trends using time seriesMarket Growth Review & Consistent Profit Focused Trading Strategies - Newser
Can trapped investors hope for a rebound in Dianthus Therapeutics Inc.Long Setup & Technical Entry and Exit Alerts - Newser
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $53.00 Consensus Target Price from Brokerages - MarketBeat
Backtesting results for Dianthus Therapeutics Inc. trading strategiesWeekly Stock Recap & Precise Entry and Exit Recommendations - Newser
Can you recover from losses in Dianthus Therapeutics Inc. [Quarterly Performance Summary]Free Reliable Trade Execution Plans - Newser
How institutional ownership impacts Dianthus Therapeutics Inc. stock [July 2025 Rallies]Free Community Verified Trade Signals - Newser
Is Dianthus Therapeutics Inc. stock poised for growthFree Weekly Setup With 3x Return Potential - Newser
Custom watchlist performance reports with Dianthus Therapeutics Inc.Strong Buy Opportunity with Volume Support - Newser
What is William Blair's Estimate for DNTH Q1 Earnings? - MarketBeat
Relative strength of Dianthus Therapeutics Inc. in sector analysisDay Trading Plan with Entry Risk Management - Newser
Has Dianthus Therapeutics Inc. formed a bullish divergenceDay Trading Setup and Momentum Analysis - Newser
How moving averages guide Dianthus Therapeutics Inc. tradingFree Triple Return Setup with Risk Control - Newser
How institutional ownership impacts Dianthus Therapeutics Inc. stockDaily Profit Watch With Forecast Confidence - Newser
Will earnings trigger a reversal in Dianthus Therapeutics Inc.Predictable Income Summary for Long-Term Trades - Newser
Dianthus Therapeutics (DNTH) to Release Earnings on Thursday - MarketBeat
Key External Factors That Drive Dianthus Therapeutics Inc. Stock Price MovementsValue Holding Return Summary With Outlook - Newser
Real time breakdown of Dianthus Therapeutics Inc. stock performancePortfolio Risk Summary & Technical Entry and Exit Alerts - Newser
Why Dianthus Therapeutics Inc. stock attracts strong analyst attentionFree Accurate Buy Point for Momentum Stocks - Newser
What makes Dianthus Therapeutics Inc. stock price move sharplyFree Consistent Gain Investment Strategies - Newser
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Is Dianthus Therapeutics Inc. still worth holding after the dipFree Reliable Investment Entry Point Signals - Newser
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates - NewsBreak: Local News & Alerts
Dianthus Therapeutics Reports Q2 2025 Financial Results - TipRanks
Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline - NewsBreak: Local News & Alerts
Dianthus Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Promising Outlook for Dianthus Therapeutics: Buy Rating on Claseprubart’s Potential in gMG - TipRanks
Dianthus Therapeutics: Promising Prospects with DNTH103 and Strong Financial Position Support Buy Rating - TipRanks
Dianthus (DNTH) Q2 Loss Widens 80% - AOL.com
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results - The Manila Times
Dianthus Therapeutics Nears Critical Phase 2 Trial Results: $309M Cash Runway Powers Multiple Clinical Programs - Stock Titan
Dianthus Therapeutics (DNTH) Expected to Announce Earnings on Thursday - Defense World
Dianthus Therapeutics Inc Azioni (DNTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):